Antibody Humanization Service

       Equipped with advanced antibody engineering technology, KMD Bioscience has built up a mature antibody production platform. The booming development of antibody-based therapeutics sees the increasing demand for humanized antibodies. Immunogenicity can potentially lead to reduced efficacy through rapid clearance or neutralization of the biosimilar, or toxicity due to cross-reaction with proteins in the body, which can have catastrophic consequences for the person. Antibody humanization reduces the immunogenicity of animal monoclonal antibodies and improves their activities in the human immune system. It is a very critical step in the therapeutic antibody discovery process.

      KMD Bioscience, supported by our antibody engineering platform, can offer efficient and accurate antibody humanization services to the scientific community. We have developed antibody humanization strategies based on our phage display technology, which can maintain the specificity and affinity of antibodies to antigens, while significantly or eliminating the immunogenicity of antibodies in humans. KMD Bioscience provides multiple strategies, such as human framework selection, CDR (Complementarity-determining regions) back mutation library screening, etc. KMD Bioscience is devoted to providing comprehensive technical services, including protein expression, antibody production, antibody purification, affinity analysis, and antibody affinity maturation.

       Workflow of antibody humanization service:  The client provides the original non-human antibody sequence, as well as any available information on the target antigen and desired therapeutic properties. KMD Bioscience will then provide guidance on the best approach for humanizing the antibody. Selection of human framework. Identification of complementarity-determining regions (CDRs). Design of humanized antibody. Antibody expression and purification. In Vitro and in vivo testing.

 

       KMD Bioscience can provide three antibody humanization strategies:

       CDR-Grafting Antibodies: This process involves transferring the antibody CDRs into a proper human antibody framework, while retaining their original affinity and specificity. Such as grafting of the murine CDRs into human frameworks.

       Chimeric Antibodies: The creation of chimeric antibodies (non-human variable regions with human constant regions) can partially alleviate immunogenic response. They were transfected to mammalian cells for recombinant antibody expression using DNA recombination technology.

       Fully Humanized Antibodies: Using gene editing technology, the antibody gene in animal somatic cells were replaced by human antibody gene, and the humanized antibodies was produced directly after animal immunization.

--Extensive experience in antibody engineering development

--Guaranteed no loss of affinity

--High throughput expression analysis

--Detailed sequence analysis

--Strict quality assurance: cGMP management rules

--A variety of antibody humanization strategies are available

--Various application validation: SPR, ELISA, FACS